Leukemia And B Cell Lymphoma Articles & Analysis
12 articles found
Fluorescence In Situ Hybridization (FISH) and Immunohistochemistry (IHC) are two powerful techniques widely used in biological and medical research. While each has its strengths, the combination of these methods—ImmunoFISH—offers a unique and comprehensive approach to investigation at the cellular and tissue levels. Understanding the Techniques FISH is primarily utilized for detecting ...
Gene editing has emerged as a transformative tool in the field of biomedical science, with significant implications for the treatment of various diseases. The primary focus is on harnessing this technology for modifying primary T cells, a type of white blood cell crucial for the immune response. This approach has opened new avenues for immunotherapy, providing hope for treating conditions like ...
Understanding Clonality Analysis Clonality refers to the origin of a cell population from a single 'parent' or progenitor cell through asexual reproduction or division. This concept is vital in cancer studies as it helps track the development of tumor cells from a single mutated cell. Clonality analysis is thus essential in understanding the evolution and the spread of cancerous cells in a ...
Understanding Clonality Analysis Clonality refers to the origin of a cell population from a single 'parent' or progenitor cell through asexual reproduction or division. This concept is vital in cancer studies as it helps track the development of tumor cells from a single mutated cell. Clonality analysis is thus essential in understanding the evolution and the spread of cancerous cells in a ...
Diseases Associated with CD19 CD19 is implicated in various significant diseases, including: 1) B-Cell Lymphoma: B-cell lymphoma, a type of leukemia and lymphoma arising from lymphoid tissue, shows overexpression of CD19 on the surface of B ...
Abstract Natural killer (NK) cells are emerging as a new tool for cell therapy of cancer. However, some cancer subtypes are relatively resistant to NK cell cytotoxicity. Expression of anti-CD19 chimeric signaling receptors can enhance NK-cell reactivity against CD19+ leukemia and lymphoma cells. Here we describe a method to enforce expression of such receptors in human NK cells relying on ...
Researchers at Massachusetts General Hospital (MGH) have found that interferon gamma receptor (IFNgR) signaling is essential for the susceptibility of CAR-T cell immunotherapy to kill malignant gliomas. The same phenomenon has been observed in other solid tumors. The findings may partially explain why liquid and solid tumors respond very differently to CAR-T cell therapy. Chimeric antigen ...
At present, chimeric antigen receptor T cell therapy (CAR-T) has made significant achievements in the treatment of specific hematological cancers, allowing patients with relapsed/refractory disease to survive longer and become healthier, but in clinical studies, cell therapy has actually not been successful in the treatment of patients with solid tumors, in part due to the lack of tumor targets ...
Simply put, CAR-T is to transform the patient's immune T cells in vitro by biotechnology, so that they recognize antigens on the surface of tumor cells, and then inject these cells back into the patient to achieve the therapeutic effect of recognizing and killing cancer cells. In 2017, CAR-T therapy was first approved by the FDA for the treatment of blood cancers such as leukemia and lymphoma. ...
Israeli-founded firm Sight Diagnostics, the company that uses AI and cutting-edge hardware to deliver rapid, complete blood count results, has signed a new research agreement with Jerusalem’s Shaare Zedek Medical Center to identify the possibility of blood cancer using a combination of images and data collected from Sight’s OLO device and patient clinical information provided by the ...
SFA Therapeutics’ CEO Dr Ira Spector presents an overview of the company and its platform technology SFA Overview Presentation on YouTube Introduction to SFA Liver Disease and Oncology Programs. SFA Oncology More information here We received US Patent 10,143,669B2; to prevent Hepatitis B progression to HCC, a liver cancer that affects 400 million patients and causes 1 million cancer ...
San Francisco, CA –Aelan Cell Technologies, with an international research team, today released a study that reveals that age is a key determining factor in the efficacy of cell-based or pharmacological treatments. ...